Arabic Arabic English English French French German German
dark

Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy

Alnylam Pharmaceuticals, Inc. today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with polyneuropathy. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Industry Veteran Rusty Williams Leads Startup to $50 Million Series A

Next Post

Successful demonstration of BioDrone® platform-based drug delivery and confirmed restoration of the myogenic potential of Prokr1-deficient C2C12 myoblasts

Related Posts
Total
0
Share